2-Pyridinylmethylsulfinylbenzimidazoles: Compounds that contain benzimidazole joined to a 2-methylpyridine via a sulfoxide linkage. Several of the compounds in this class are ANTI-ULCER AGENTS that act by inhibiting the POTASSIUM HYDROGEN ATPASE found in the PROTON PUMP of GASTRIC PARIETAL CELLS.Sulfoxides: Organic compounds that have the general formula R-SO-R. They are obtained by oxidation of mercaptans (analogous to the ketones). (From Hackh's Chemical Dictionary, 4th ed)Dictionaries, ChemicalDictionaries, MedicalDictionaries as Topic: Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.Myocytes, Smooth Muscle: Non-striated, elongated, spindle-shaped cells found lining the digestive tract, uterus, and blood vessels. They are derived from specialized myoblasts (MYOBLASTS, SMOOTH MUSCLE).Adrenochrome: Pigment obtained by the oxidation of epinephrine.Coordination Complexes: Neutral or negatively charged ligands bonded to metal cations or neutral atoms. The number of ligand atoms to which the metal center is directly bonded is the metal cation's coordination number, and this number is always greater than the regular valence or oxidation number of the metal. A coordination complex can be negative, neutral, or positively charged.KetonesVolatile Organic Compounds: Organic compounds that have a relatively high VAPOR PRESSURE at room temperature.Transition Elements: Elements with partially filled d orbitals. They constitute groups 3-12 of the periodic table of elements.
(1/641) Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study.

BACKGROUND: Rabeprazole sodium is the newest member of a class of substituted benzimidazole molecules known as proton pump inhibitors. Other proton pump inhibitors have been shown to be effective in healing active duodenal ulcer. METHOD: This randomized, double-blind, multicentre study, conducted at 25 European sites, compared the efficacy and tolerability of rabeprazole and omeprazole in patients with active duodenal ulcers. One hundred and two patients with active duodenal ulcer received rabeprazole 20 mg and 103 patients omeprazole 20 mg once daily for 2 or 4 weeks, with ulcer healing monitored by endoscopy. RESULTS: After 2 weeks, complete ulcer healing was documented in 69% of patients given rabeprazole 20 mg and in 62% of patients given omeprazole 20 mg (N.S.). After 4 weeks, healing rates were 98% in the rabeprazole group and 93% in the omeprazole group (P = 0.083). Rabeprazole-treated patients had significantly greater improvement in daytime pain symptom relief than those treated with omeprazole at the conclusion of the study (P = 0.038). Both drugs were well tolerated over the 4-week treatment period. Mean changes from baseline to end-point in fasting serum gastrin were significantly greater in the rabeprazole group, but at end-point mean values were well within normal limits for both groups. No clinically meaningful changes or other between-group differences were observed in laboratory parameters. CONCLUSION: In this study, rabeprazole produced healing rates equivalent to omeprazole at weeks 2 and 4, and provided significantly greater improvement in daytime pain. Both treatments were well tolerated.  (+info)

(2/641) Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection.

BACKGROUND: A furazolidone-containing therapeutic regimen for Helicobacter pylori infection has attracted special interest in the face of a rising world-wide metronidazole resistant H. pylori, and the expense of currently used antimicrobial regimens. AIM: To evaluate the efficacy of furazolidone-containing regimens in eradicating H. pylori. METHODS: One-hundred and forty H. pylori positive patients with endoscopically confirmed duodenal ulcer or functional dyspepsia received one of four different regimens to eradicate H. pylori. In the first trial, the patients were randomly assigned to receive a 1-week course of furazolidone 100 mg b.d. and clarithromycin 250 mg b.d., with either tripotassium dicitrato bismuthate (TDB) 240 mg b.d. (FCB group) or lansoprazole 30 mg daily (FCL group). In the second trial, the patients were randomly assigned to receive a 1-week course of clarithromycin 250 mg b.d. and omeprazole 20 mg daily, with either furazolidone 100 mg b.d. (FCO group) or metronidazole 400 mg b.d. (MCO group). Endoscopy was repeated 4 weeks following completion of therapy with re-assessment of H. pylori status on gastric biopsies by histology and culture. RESULTS: Four patients (1 in FCB, 1 in FCO and 2 in MCO groups) dropped out because they refused a follow-up endoscopy. Eradication rates of H. pylori on an intention-to-treat basis in the FCB, FCL, FCO and MCO groups were 91% (32/35, 95% CI: 82-99%), 91% (32/35, CI: 82-99%), 86% (30/35, CI: 74-97%) and 74% (26/35, CI: 60-89%) (all P > 0.05), respectively. Mild side-effects occurred in 15% of the 140 patients. In MCO group, the eradication rate in the patients infected with metronidazole-sensitive isolates of H. pylori was 86%, but dropped to 67% in those with metronidazole-resistance strains (P = 0.198). CONCLUSION: One-week regimens containing furazolidone and clarithromycin in combination with TDB or a proton pump inhibitor fulfil the criteria for successful H. pylori therapy.  (+info)

(3/641) Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia.

AIM: To compare the relative efficacies of lansoprazole 15 mg o.m. and omeprazole 10 mg o.m. in relieving heartburn and epigastric pain in patients with acid-related dyspepsia. In addition, the study compared the safety profiles of the two treatments. METHODS: This double-blind, parallel group, randomised, multicentre study was conducted in 52 general practices in the UK. A total of 609 patients was recruited, 562 of whom were eligible for inclusion in the intention-to-treat analysis. All of the patients had experienced at least mild heartburn or mild epigastric pain persistently on at least 4 of the previous 7 days; patients with severe symptoms were excluded. 283 patients received lansoprazole 15 mg and 279 received omeprazole 10 mg, both for 4 weeks. The main efficacy measure was relief of symptoms, based on physician assessments. RESULTS: In the intention-to-treat population, a complete relief of overall primary symptoms of dyspepsia was achieved after 2 weeks in 53% of patients receiving lansoprazole and in 41% of patients receiving omeprazole (P = 0.007). After 4 weeks, 59% of the lansoprazole group and 51% of the omeprazole group had achieved complete symptom relief (P = 0. 078). Antacids were taken for additional relief of symptoms in fewer patients given lansoprazole compared to the omeprazole group in the third and fourth weeks (P = 0.035) and also significantly fewer antacids were taken by patients in the lansoprazole group compared with patients in the omeprazole group (P = 0.033). The proportion of patients reporting adverse events was similar in both groups. CONCLUSION: Low-dose lansoprazole is more effective than low-dose omeprazole in the treatment of patients with mild heartburn or epigastric pain in general practice.  (+info)

(4/641) Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection.

AIM: To evaluate the efficacy of polaprezinc, a mucosal protective agent, in combination with a 7-day triple therapy containing lansoprazole, amoxycillin and clarithromycin, as a treatment for Helicobacter pylori. METHODS: Sixty-six consecutive patients suffering from dyspeptic symptoms with H. pylori infection were randomly allocated to one of two regimens: one group (LAC; n = 31) received lansoprazole 30 mg b.d., amoxycillin 500 mg b.d. and clarithromycin 400 mg b.d. for 7 days. The other group (LACP; n = 35) received the LAC regimen plus polaprezinc 150 mg b.d. for 7 days. H. pylori status was evaluated by rapid urease test, histology and culture at entry and 4 weeks after treatment. RESULTS: Five patients did not complete the treatment: no follow-up endoscopy was performed on two patients in the LAC group; one patient in the LAC group and two in the LACP group had their treatment stopped due to severe diarrhoea. By per protocol analysis, H. pylori eradication was achieved in 24 of the 28 evaluable patients (86%; 95% CI: 72-100%) after LAC therapy, and in 33 of the 33 evaluable patients (100%) after LACP therapy (P < 0.05). On intention-to-treat analysis, the rates of eradication were 24 of 31 patients (77%; 95% CI: 62-93%) in the LAC group, and 33 of 35 patients (94%; 95% CI: 86-100%) in the LACP group (P < 0.05). CONCLUSION: A 7-day triple therapy with lansoprazole, amoxycillin and clarithromycin is effective in H. pylori eradication, but this regimen is significantly improved by the addition of polaprezinc.  (+info)

(5/641) The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen.

BACKGROUND: Current guidelines for Helicobacter pylori eradication recommend 7 days of a proton-pump inhibitor, clarithromycin (C), and either metronidazole (M) or amoxycillin (A). A shorter course would be cheaper and could be as effective. AIM: This study was designed to investigate the efficacy of three 5-day regimens based on lansoprazole (L). METHODS: 168 dyspepsia patients with H. pylori infection were randomized to receive a 5-day course of either LCM, LAC or CALM, and a 13C-urea breath test was performed after 4 weeks to assess eradication. RESULTS: 160 patients completed the study. Intention-to-treat eradication rates were as follows: LCM 81%, LAC 59%, CALM 88%. LCM and CALM gave significantly better eradication rates than LAC. There was no significant difference in adverse events across the three groups. Logistical regression analysis showed that the specific regimen used and the age of the patient were the only factors influencing eradication outcome. CONCLUSIONS: Five days of CALM yields acceptable eradication rates, and is cheaper than conventional 7-day proton pump inhibitor-triple therapy. It appears to offer good results in metronidazole-resistant strains of H. pylori. A randomized trial comparing 5-day CALM with conventional 7-day therapy is needed before this regimen can be recommended for routine use.  (+info)

(6/641) The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori.

BACKGROUND: Resistance of Helicobacter pylori to antibiotics may be a major reason for treatment failure. AIM: To evaluate the effect of primary H. pylori resistance to antibiotics on the cure rates of three anti-H. pylori 1-week triple therapies. METHODS: One hundred and sixteen consecutive patients diagnosed H. pylori-positive by gastric histology, rapid urease test and culture were enrolled. Activity of tested antibiotics was determined by means of the E-test. Patients were treated for 7 days with: (i) pantoprazole 40 mg o.d. plus amoxycillin 1 g b.d. and metronidazole 250 mg q.d.s. (PAM); (ii) pantoprazole 40 mg o.d. plus clarithromycin 250 mg b.d. and metronidazole 250 mg q.d.s. (PCM); or (iii) pantoprazole 40 mg o.d. plus amoxycillin 1 g b.d. and clarithromycin 250 mg b.d. (PAC). Two months after completion of therapy, endoscopy and gastric biopsies were repeated. RESULTS: Primary resistance rates to metronidazole, clarithromycin and amoxycillin were 17.2, 6.9 and 0%, respectively. Overall H. pylori cure rates expressed as intention-to-treat and per protocol analyses were, respectively, 79% and 86% with PAM, 82% and 89% with PCM, and 85% and 85% with PAC. Significantly lower cure rates were observed in metronidazole-resistant patients treated with PAM (56% vs. 96%, P = 0.01) or PCM (50% vs. 97%, P = 0.01). A trend towards lower H. pylori cure rates was observed in clarithromycin-resistant patients treated with PCM (67% vs. 91%, P = 0.74) or PAC (50% vs. 87%, P = 0.68). CONCLUSION: Primary resistance to metronidazole influences the H. pylori cure rate of anti-H. pylori proton pump inhibitor-based triple therapies which include this antibiotic. A similar trend exists for primary clarithromycin resistance.  (+info)

(7/641) Treatment of H. pylori infection: the reality.

Despite the wide dissemination of information on Helicobacter pylori, there is still a great deal of variation in how general practitioners treat the infection and in which circumstances they prescribe eradication therapy for H. pylori. Specialty societies have developed consensus guidelines that recommend a strategy to test and treat dyspeptic patients for H. pylori infection although the data to support these recommendations are weak at the present time. As a result, there is still confusion about the indications for treatment and the treatment regimens that are likely to be effective in routine clinical practice.  (+info)

(8/641) The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine.

BACKGROUND: The antisecretory effect of omeprazole on intragastric pH is decreased in the absence of Helicobacter pylori. AIM: To investigate the effect of H. pylori eradication on intragastric pH during lansoprazole or ranitidine dosing in 41 asymptomatic H. pylori-positive subjects. METHOD: Two groups of healthy H. pylori-positive volunteers were investigated. One group was dosed with lansoprazole 30 mg at 08.00 hours for at least 8 days, before and after 2 weeks of placebo-controlled double-blind eradication therapy using ranitidine bismuth citrate 400 mg b.d. and clarithromycin 500 mg b.d. The other group was dosed with ranitidine 300 mg at 23.00 hours for at least 8 days using the same trial design. An upper endoscopy was performed to establish H. pylori status by rapid urease test, culture and histology before both periods of dosing. Twenty-four hour intragastric pH recording was performed on the final day of all periods of dosing. RESULTS: H. pylori eradication significantly decreased the intragastric pH reached during lansoprazole treatment throughout all periods of the day. Intragastric pH during ranitidine treatment was not affected by H. pylori eradication, except for the late-night period. CONCLUSION: H. pylori eradication has a more pronounced effect on the acid-inhibiting properties of lansoprazole than on those of ranitidine.  (+info)

*  Discovery and development of proton pump inhibitors
Proton pump inhibitors (PPIs) block the gastric hydrogen potassium ATPase (H+/K+ ATPase) and inhibit gastric acid secretion. These drugs have emerged as the treatment of choice for acid-related diseases, including gastroesophageal reflux disease (GERD) and peptic ulcer disease. PPIs also can bind to other types of proton pumps such as those that occur in cancer cells and are finding applications in the reduction of cancer cell acid efflux and reduction of chemotherapy drug resistance. Evidence emerged by the end of the 1970s that the newly discovered proton pump (H+/K+ ATPase) in the secretory membrane of the parietal cell was the final step in acid secretion. Literature from anaesthetic screenings led attention to the potential antiviral compound pyridylthioacetamide which after further examination pointed the focus on an anti-secretory compound with unknown mechanisms of action called timoprazole. Timoprazole is a pyridylmethylsulfinyl benzimidazole and appealed due to its simple chemical ...
*  Magnesium monoperoxyphthalate
... (MMPP) is a water-soluble peroxy acid used as an oxidant in organic synthesis. Its main areas of use are the conversion of ketones to esters (Baeyer-Villiger oxidation), epoxidation of alkenes (Prilezhaev reaction), oxidation of sulfides to sulfoxides and sulfones, oxidation of amines to produce amine oxides, and in the oxidative cleavage of hydrazones. Due to its insolubility in nonpolar solvents MMPP has seen less use than the more widely used meta-chloroperoxybenzoic acid (mCPBA). Although work up procedures are more simply handled in polar solvents, usage of MMPP to oxidize nonpolar substrates in biphasic media combined with a phase transfer catalyst have been inefficient. Despite this MMPP has certain advantages over mCPBA including a lower cost of production and increased stability. MMPP is also used as the active ingredient in certain surface disinfectants such as Dismozon Pur. As a surface disinfectant MMPP exhibits a broad spectrum biocidal effect including ...
*  Organoselenium chemistry
Organoselenium compounds are chemical compounds containing carbon-to-selenium chemical bonds. Organoselenium chemistry is the corresponding science exploring their properties and reactivity. Selenium belongs with oxygen and sulfur to the group 16 elements or chalcogens, and similarities in chemistry are to be expected. Selenium can exist with oxidation state -2, +2, +4, +6. Se(II) is the dominant form in organoselenium chemistry. Down the group 16 column, the bond strength becomes increasingly weaker (234 kJ/mol for the C-Se bond and 272 kJ/mol for the C-S bond) and the bond lengths longer (C-Se 198 pm, C-S 181 pm and C-O 141 pm). Selenium compounds are more nucleophilic than the corresponding sulfur compounds and also more acidic. The pKa values of XH2 are 16 for oxygen, 7 for sulfur and 3.8 for selenium. In contrast to sulfoxides, the corresponding selenoxides are unstable in the presence of β-protons and this property is utilized in many organic reactions of selenium, notably in selenoxide ...
*  Flavin-containing monooxygenase
The flavin-containing monooxygenase (FMO) protein family specializes in the oxidation of xeno-substrates in order to facilitate the excretion of these compounds from living organisms. These enzymes can oxidize a wide array of heteroatoms, particularly soft nucleophiles, such as amines, sulfides, and phosphites. This reaction requires an oxygen, an NADPH cofactor, and an FAD prosthetic group. FMOs share several structural features, such as a NADPH binding domain, FAD binding domain, and a conserved arginine residue present in the active site. Recently, FMO enzymes have received a great deal of attention from the pharmaceutical industry both as a drug target for various diseases and as a means to metabolize pro-drug compounds into active pharmaceuticals. These monooxygenases are often misclassified because they share activity profiles similar to those of cytochrome P450 (CYP450), which is the major contributor to oxidative xenobiotic metabolism. However, a key difference between the two enzymes ...
*  Urban Dictionary
... é um site que contém um dicionário de gírias e frases em inglês. Desde 2009, o site contém mais de quatro milhões de definições. As inscrições são reguladas por editores voluntários e avaliadas pelos visitantes do site. Aaron Peckham fundou o site em 1999. Anita Hamilton of Time incluiu o Urban Dictionary sua lista dos 50 melhores sites de 2008. «Article: Interview: Aaron Peckham talks about his on-line, interaction slang dictionary site, UrbanDictionary.com - NPR Weekend Edition - Sunday , HighBeam Research - FREE trial». Highbeam.com. Consultado em 25 de junho de 2017 «50 Best Web Sites - Podcast». TIME. Consultado em 25 de junho de 2017 «Urban Dictionary - 50 Best Websites 2008». TIME. Consultado em 25 de junho de 2017 urbandictionary.com (em inglês) Street Smart: Urban Dictionary (em inglês ...
*  Urban Dictionary
... è un dizionario online dedicato ai neologismi e allo slang in lingua inglese. Lanciato nel 1999 da Aaron Peckham, il sito web contiene più di 4,8 milioni di definizioni, aggiunte da volontari e votate dai visitatori. Il sito è stato poi trasposto in forma cartacea in due edizioni, nel 2005 e nel 2007. Anita Hamilton del TIME lo ha inserito in una classifica dedicata ai migliori 50 siti. Secondo un'analisi LexisNexis presente nel saggio Wikipedia in Court, dedicato all'uso di siti come Wikipedia come fonti autorevoli, fino al 10 settembre 2009 l'Urban Dictionary è stato citato 22 volte in casi giudiziari statunitensi. Aaron Peckham, Urban Dictionary: Fularious Street Slang Defined , Andrews McMeel, 2005, pagg. 320, ISBN 0-7407-5143-3 Aaron Peckham, Mo' Urban Dictionary: Ridonkulous Street Slang Defined, Andrews McMeel, 2007, pagg. 230, ISBN 0-7407-6875-1 ^ (EN) Steve Inskeep, Transcript: Interview: Aaron Peckham talks about his on-line, interaction slang dictionary site, ...
*  Easton's Bible Dictionary
The Illustrated Bible Dictionary,[a] better known as Easton's Bible Dictionary, is a reference work on topics related to the Christian Bible compiled by Matthew George Easton. The first edition was published in 1893,[1] and a revised edition was published the following year.[2] The most popular edition, however, was the third, published by Thomas Nelson in 1897, three years after Easton's death.[3] The last contains nearly 4,000 entries relating to the Bible. Many of the entries in Easton's are encyclopedic in nature, although there are also short dictionary-type entries.. Because of its age, it is now a public domain resource.. ...
*  Telureto de dimetilo
... é um composto organotelureto, com fórmula (CH3)2Te, também conhecido pela abreviação DMTe. Este material foi o primeiro usado para o crescimento epitaxial de telureto de cádmio e telireto de mercúrio e cádmio usando epitaxia de fase vapor metalorgânica. Telureto de dimetilo como um produto de metabolismo microbiano foi primeiramente descoberto em 1939. Telureto de dimetilo é produzido por alguns fungos e bactérias (Penicillium brevicaule, P. chrysogenum e P. notatum e a bactéria Pseudomonas fluorescens). A toxicidade do DMTe não é clara. É produzido pelo corpo quando telúrio ou um dos seus compostos são ingeridos. É notável pela seu cheiro similar a alho (lembra alho apodrecendo na ausência de ar). Telúrio é conhecido por ser tóxico. «dimethyl telluride (CHEBI:4613)». Chemical Entities of Biological Interest (ChEBI). UK: European Bioinformatics Institute. 25 de setembro de 2006. IUPAC Names. Consultado em 19 de setembro de 2011 J. Tunnicliffe, S. J. ...
*  Fenil-lítio
... é um agente organometálico com a fórmula empírica C6H5Li. É mais comumente utilizado como um agente de metalização em sínteses orgânicas e um substituto para reagentes de Grignard para a introdução de grupos fenilo em sínteses orgânicas. Fenil-lítio cristalino é incolor, no entanto, as soluções de fenil-lítio apresentam vários tons de cor marrom ou vermelho, dependendo do solvente utilizado e das impurezas presentes no soluto. «phenyllithium (CHEBI:51470)». Chemical Entities of Biological Interest (ChEBI). UK: European Bioinformatics Institute. 22 de janeiro de 2009. Main. Consultado em 27 de setembro de 2011 Predefinição:ChemBlink Wietelmann, U.; Bauer, R.J. "Lithium and Lithium Compounds" in Ullmann's Encyclopedia of Industrial Chemistry, 2002, Wiley-VCH, Weinheim. doi:10.1002/14356007.a15 Gilman, H.; Zoellner, E.A.; Selby, W.M. An Improved Procedure for the Preparation of Organolithium Compounds. J. Am. Chem. Soc. 1932 54 (5), 1957-1962. doi:10.1021/ ...
*  Aspidospermidin - Википедија, слободна енциклопедија
Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry. 4: 217-241. doi:10.1016/S1574-1400(08)00012-1 ...
*  Kamfen - Википедија, слободна енциклопедија
Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry. 4: 217-241. doi:10.1016/S1574-1400(08)00012-1 ...
*  Skvalan - Википедија, слободна енциклопедија
Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry. 4: 217-241. doi:10.1016/S1574-1400(08)00012-1 ...
*  Trehaloza dimikolat - Википедија, слободна енциклопедија
Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry. 4: 217-241. doi:10.1016/S1574-1400(08)00012-1 ...
Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal...  Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal...
2-Pyridinylmethylsulfinylbenzimidazoles / therapeutic use*. Adult. Aged. Aged, 80 and over. Anti-Ulcer Agents / therapeutic use ... 0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 0/Histamine H2 Antagonists; 0/Proton Pumps; 32828355LL/ ... that was defined as hematemesis or melena that required endoscopic hemostasis and decreased the hemoglobin count by more than 2 ...
more infohttp://www.biomedsearch.com/nih/Effect-proton-pump-inhibitor-H2/17403076.html
Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis?  Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis?
2-Pyridinylmethylsulfinylbenzimidazoles / therapeutic use*. Adult. Aged. Anti-Ulcer Agents / therapeutic use*. Disease ... 0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 0/Proton Pumps; 103577-45-3/lansoprazole ...
more infohttp://www.biomedsearch.com/nih/Does-long-term-therapy-with/19796554.html
Aspirin/esomeprazole - AdisInsight  Aspirin/esomeprazole - AdisInsight
Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiplatelets; Antipyretics; Antirheumatics; Antiulcers; Gastric antisecretories ...
more infohttps://adisinsight.springer.com/drugs/800032679?error=cookies_not_supported&code=699d407a-d678-484e-b970-6dff2f499932
Expert Position Paper on the Use of Proton Pump Inhibitors in Patients With Cardiovascular Disease and Antithrombotic Therapy -...  Expert Position Paper on the Use of Proton Pump Inhibitors in Patients With Cardiovascular Disease and Antithrombotic Therapy -...
Keywords: Vitamin K, Thiophenes, Warfarin, 2-Pyridinylmethylsulfinylbenzimidazoles, Piperazines, Ticlopidine, Gastroesophageal ... 2. So far, there are insufficient data to suggest a clinical interaction between PPI use and the protective efficacy of aspirin ...
more infohttp://www.acc.org/latest-in-cardiology/journal-scans/2013/02/27/16/20/expert-position-paper-on-the-use-of-proton-pump-inhibitors
AJOU Open Repository: Browsing DSpace  AJOU Open Repository: Browsing DSpace
1 2',5'-Oligoadenylate Synthetase/blood * 1 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/analogs & derivatives/* ...
more infohttp://repository.ajou.ac.kr/browse?type=subject&order=ASC&rpp=60&starts_with=0
NAVER 학술정보 >...  NAVER 학술정보 >...
2007 Andree Beckerling 외 2 명 DIGESTION 0회 피인용 Anti-Ulcer Agents, administration & dosage, Clinical Medicine, standards, trends ... 2-Pyridinylmethylsulfinylbenzimidazoles, administration & dosage, Adult, Aged, Cross-Over Studies, Dose-Response Relationship, ... 2-Pyridinylmethylsulfinylbenzimidazoles, administration & dosage, Adult, Drug Administration Schedule, Esophagoscopy, Female, ...
more infohttps://academic.naver.com/search.naver?field=3&query=DIGESTION+75+Suppl+1%EA%B6%8C+1%ED%98%B8
NAVER Academic > Search...  NAVER Academic > Search...
Healing of duodenal ulcers is not impaired by indomethacin or rofecoxib, the selective COX-2 inhibitor, in rats.. 2002 Hideo ... 2-Pyridinylmethylsulfinylbenzimidazoles, Adult, Amoxicillin, therapeutic use, Anti-Ulcer Agents, Benzimidazoles, Clarithromycin ...
more infohttps://academic.naver.com/search.naver?field=3&query=DIGESTION+66%EA%B6%8C+3%ED%98%B8
The influence of pretreatment on cure rates of Helicobacter pylori eradication.  - PubMed - NCBI  The influence of pretreatment on cure rates of Helicobacter pylori eradication. - PubMed - NCBI
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
more infohttps://www.ncbi.nlm.nih.gov/pubmed/15460498
Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial.  -...  Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. -...
2013 Apr;18(2):129-34. doi: 10.1111/hel.12017. Epub 2012 Nov 4. Clinical Trial; Comparative Study; Randomized Controlled Trial ... Helicobacter. 2013 Apr;18(2):129-34. doi: 10.1111/hel.12017. Epub 2012 Nov 4. ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/23121338?dopt=Abstract
Lansoprazole - DrugBank  Lansoprazole - DrugBank
2. 3. Recruiting. Treatment. Anti-Ulcer Agents / Digestive System Diseases / Enzyme Inhibitors / Gastric Ulcer (GU) / ... CYP2C19*2. (A;A). A Allele, homozygote. Effect Directly Studied. Patients with this genotype have reduced metabolism of ... 1996 May;277(2):805-16. [PubMed:8627562] *Kim KA, Kim MJ, Park JY, Shon JH, Yoon YR, Lee SS, Liu KH, Chun JH, Hyun MH, Shin JG ... 2. Recruiting. Treatment. Cervical Cancers / Endometrial Cancers / Uterine Malignancies. 1. 2. Recruiting. Treatment. Gastric ...
more infohttps://www.drugbank.ca/drugs/DB00448
Domperidone | Profiles RNS  Domperidone | Profiles RNS
Hartwell HJ, Petrosky KY, Fox JG, Horseman ND, Rogers AB. Prolactin prevents hepatocellular carcinoma by restricting innate immune activation of c-Myc in mice. Proc Natl Acad Sci U S A. 2014 Aug 5; 111(31):11455-60 ...
more infohttps://profiles.umassmed.edu/display/127482
Search Articles | University of Toronto Libraries  Search Articles | University of Toronto Libraries
transcription factors - genetics (2) 2 Filter by. Remove filter. 2-pyridinylmethylsulfinylbenzimidazoles - therapeutic use (1) ... Pathology , INDUCIBLE CRE RECOMBINASE , SLIT DIAPHRAGM , NEPHRIN , D-ASPARTATE RECEPTORS , DISEASE , PROTEIN MAGI-2 , DEFICIENT ... 2. Full Text Collection, Mapping, and Annotation of over 28,000 cDNA Clones from Japonica Rice ... Full Text MAGI-2 Is Critical for the Formation and Maintenance of the Glomerular Filtration Barrier in Mouse Kidney ...
more infohttps://query.library.utoronto.ca/index.php/search/q?kw=Author:Midori%20Kawamata
Search Articles | University of Toronto Libraries  Search Articles | University of Toronto Libraries
2. Full Text A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the ... Bcl-2 protein , Laboratories , Liver , Glycine , Caspase-3 , Proteins , Elevation , Arginine , Betaine , Rodents , DNA ... 2-Pyridinylmethylsulfinylbenzimidazoles - therapeutic use , Helicobacter Infections - drug therapy , Ofloxacin - administration ...
more infohttps://query.library.utoronto.ca/index.php/search/q?kw=Author:Pacana,%20Tommy
Domperidone | Colorado PROFILES  Domperidone | Colorado PROFILES
Parker SL, Armstrong WE, Sladek CD, Grosvenor CE, Crowley WR. Prolactin stimulates the release of oxytocin in lactating rats: evidence for a physiological role via an action at the neural lobe. Neuroendocrinology. 1991 May; 53(5):503-10 ...
more infohttps://profiles.ucdenver.edu/display/219055
Proton Pump Inhibitors | ISHAR Online  Proton Pump Inhibitors | ISHAR Online
The general pharmacological properties of YJA 20379-1 (2-amino-4,5-dihydro-8-phenylimidazo[2,1-b]thiazolo[4,5-g]benzo thi azole ... The general pharmacological profiles of a novel proton pump inhibitor, (+/-)-5-methoxy-2-[[(4-methoxy-3,5-dimethylpyrid-2-yl) ... General pharmacological properties of the new proton pump inhibitor (+/-)-5-methoxy-2-[[(4-methoxy-3,5-dimethylpyrid-2-yl) ...
more infohttp://isharonline.org/tags/proton-pump-inhibitors
Helicobacter pylori | ISHAR Online  Helicobacter pylori | ISHAR Online
2 natural and 15 semisynthetic molecules), including eight newly synthesized compounds, were investigated against clinical and ...
more infohttp://isharonline.org/tags/helicobacter-pylori
Sulfoxides | CTD  Sulfoxides | CTD
2,3,4,6-. tetra-. O-. benzylgalactopyranosyl phenyl sulfoxide 2-. (4-. (2,2-. dimethyl-. 1,3-. dioxan-. 5-. yl)methoxy-. 3,5- ... 1,2,4-. oxadiazole 3-. chloro-. N-. ((3,4-. dihydro-. 2-. methyl-. 4-. oxo-. 6-. quinazolinyl)methyl)-. 4-. (phenylsulfinyl)-. ... 2-. methylsulfinylphenyl)-. 1-. piperidinyl)butyl)-. N-. methyl-. 3-. cyano-. 1-. naphthamide N-. acetyl-. S-. -. (1,2,3,4,4- ... 2-. fluoroethyl)(4-. (4-. nitrophenylsulfinyl)phenyl)amino)acetate ethyl-. 6-. bromo-. 5-. hydroxy-. 4-. (imidazol-. 1-. yl)-. ...
more infohttp://ctdbase.org/detail.go?type=chem&acc=D013454
  • Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. (naver.com)
  • Healing of duodenal ulcers is not impaired by indomethacin or rofecoxib, the selective COX-2 inhibitor, in rats. (naver.com)
  • 2. So far, there are insufficient data to suggest a clinical interaction between PPI use and the protective efficacy of aspirin in patients with cardiovascular disease. (acc.org)